Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLB 001 LPS Challenge Study
NCT05765955Phase 1Completed
- Sponsor
- Poolbeg Pharma
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of POLB 001 in influenza and cytokine release syndrome (CRS) (4 arms), sponsored by Poolbeg Pharma. Primary endpoints: Effect of intradermal and intravenous LPS challenge on inflammatory responses at 16 days, Effect of LPS challenge on clinical parameters at 16 days and 1 more. Started Jul 2022; status: completed.
02
Drugs
POLB 001
03
Conditions
influenzacytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT05765955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765955.